Navigation Links
CareGuide Adds New Management Team Members
Date:7/13/2009

CORAL SPRINGS, Fla., July 13 /PRNewswire/ -- CareGuide, Inc., an emerging health management company, welcomes Julie Sizemore as Senior Vice President of Operations and Marise Condon as Area Vice President of Sales. Both are located in Texas and Julie Sizemore will work from the CareGuide Dallas, Texas operations location.

Julie Sizemore (www.careguide.com/about/people/jsizemore) leads operational, clinical and developmental aspects of all CareGuide products and services. She provides strategic direction for Company operations as it expands to accommodate new and innovative programs. Prior to joining CareGuide, Julie was COO of Nurtur Health, a subsidiary of Centene Corporation created from the merger of AirLogix and Cardium Health. Prior to that, Julie was the Vice President of Clinical Operations at AirLogix. She has a long proven record of accomplishment in the case management and disease management industry.

Marise Condon (www.careguide.com/about/people/mcondon) will grow and develop our business as the foundation of our sales team. Marise brings more than 20 years of managed care and business development experience, including clients in the health plan, state government and employer sectors. Prior to joining CareGuide, she was the Director of Corporate Development at Casenet. Prior to that role, she was Vice President and Regional Director of Business Development at ParadigmHealth as well as Area Vice President of Sales for AirLogix (Centene Corporation). Marise has been a successful sales executive, drawing from her clinical expertise as a registered nurse to develop tailored solutions for clients.

Michael Condron, CEO at CareGuide, remarks about the new executives, "Julie Sizemor
'/>"/>

SOURCE CareGuide, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Case Management Cost-Effective Way to Cut Heart Risks
2. S.C. BlueCross to Integrate Care Management with Personal Health Record in Real Time
3. Marlabs in the Top 10 BPO Healthcare Revenue Cycle Management Companies
4. Painless Hemorrhoid Treatment Adds Management Punch
5. HealthFitness CEO Supports Move Toward Cultural Shift, and Science-Based Health Management Programming
6. Judge Rules That Florida Disease Management Program Serving 8,000 HIV/AIDS Patients Should Be Re-bid, Says AIDS Healthcare Foundation
7. Standard Management Announces OTCBB Listing
8. MDS Pharma Services Wins Award for Management of Global Malaria Trial
9. AWT Management Announce Aggressive Growth and Acquisition Strategy
10. Hospital Workers: Management Threatens Patient Care
11. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 1Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 2Researchers Find Common Respiratory Virus Hijacks Lung Cells to Stay Alive 4946 3NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 1NACDS 3A Court Ruling on AWPs Shifts 26quot 3BUrgency for Action 26quot 3B to States 56288 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 1NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 3NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 4